The HADH Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of the human HT29 colorectal adenocarcinoma cell line, engineered to disrupt expression of the HADH gene. This pooled knockout model provides researchers with a genetically heterogeneous loss-of-function system suitable for studying the roles of short-chain 3-hydroxyacyl-CoA dehydrogenase in cancer cell metabolism. The polyclonal format preserves the inherent cellular diversity of the host line while introducing targeted gene disruption, enabling robust population-level analyses of metabolic adaptation and therapeutic responses.
The HT29 host cell line was derived from a primary colon tumor of a 44-year-old Caucasian female and exhibits epithelial morphology characteristic of colorectal adenocarcinoma. Widely employed in colon cancer research and drug screening, HT29 cells serve as a well-established intestinal epithelial model for investigating tumor biology, differentiation, and oncogenic signaling. Their use in knockout studies facilitates the dissection of metabolic pathways that may contribute to the Warburg effect and other cancer-associated metabolic shifts, while maintaining relevance to the colorectal tumor microenvironment.
HADH encodes the mitochondrial enzyme short-chain 3-hydroxyacyl-CoA dehydrogenase, which catalyzes the third step in the beta-oxidation of short-chain fatty acids. This homodimeric enzyme utilizes NAD+ as a cofactor to oxidize substrates such as octanoyl-CoA, generating reducing equivalents for the electron transport chain. HADH activity is transcriptionally regulated by PPARA, PGC1A, HNF4A, and the nutritional sensor SIRT3, and it plays a critical role in modulating the acetyl-CoA pool and TCA cycle flux. Functionally, HADH influences insulin secretion in pancreatic beta-cells by controlling the ATP/ADP ratio that governs ATP-sensitive potassium channels composed of KCNJ11 (Kir6.2) and ABCC8 (SUR1). Consequently, HADH integrates fatty acid oxidation with cellular energy status, impacting mitochondrial membrane potential and insulin exocytosis.
In the context of HT29 colorectal cancer cells, HADH knockout is expected to abolish short-chain fatty acid beta-oxidation, decreasing acetyl-CoA availability and forcing metabolic reliance on glycolysis. This metabolic reprogramming may mimic aspects of the Warburg effect and alter lipid homeostasis, providing a powerful model to study how cancer cells adapt to impaired mitochondrial fatty acid metabolism. The disruption of HADH also holds relevance for investigating congenital hyperinsulinemic hypoglycemia mechanisms, as loss-of-function mutations in HADH lead to dysregulated insulin secretion. Therefore, these cells serve as a platform to examine the interplay between beta-oxidation and insulin signaling in a colorectal cancer background.
Researchers can employ these polyclonal knockout cells in a variety of functional assays, including palmitate oxidation studies, Seahorse metabolic flux analyses, and targeted metabolomics to quantify changes in acetyl-CoA and TCA cycle intermediates. Applications extend to drug screening for agents that target metabolic vulnerabilities, proliferation assays (such as MTT or colony formation), apoptosis detection by flow cytometry, and insulin secretion ELISA when engineered to express insulin. Immunofluorescence for mitochondrial markers and immunoblotting or RT-qPCR for HADH and associated enzymes (e.g., ACADS, ECHS1, ACAT1) further enable detailed mechanistic investigations. For additional information or to acquire this product, please reach out to Ascent Research.
